Alex Colville
General Partner @ age1
San Francisco, United States
Alex Colville is a General Partner at age1.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Alex Colville invests in
Stages Alex Colville invests in
Countries Alex Colville invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (100%)
- Pet 1 (50%)
- Veterinary 1 (50%)
Stage
- Series A 1 (50%)
- Series C 1 (50%)
Country
- Ireland 1 (50%)
- United States 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $100M / Series C / Feb 11, 2026 | ||
| Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $39M / Series A / Feb 09, 2026 |
Co-Investors
About age1
Longevity is at an inflection point. Due to scientific advances over the last 30 years, we are beginning to change how we interact with chronological age, living a longer number of healthy years than ever before. Here and now, we embark on this journey. Longevity Fund is launching Age 1, a 4-month program based in SF which offers both capital andhelp to launch founder-driven biotechnology companies. We are selecting a small group of innovative scientists and technologists who are working to extend human healthspan to bring to San Francisco.
age1 Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alex Colville
General Partner
|
|||
Laura Deming
Partner
|
|||
Omri Amirav-Drory
Mentor
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alex Colville invest in?
Alex Colville invests primarily in Biotechnology, Pet and Veterinary startups, most often at Series A and Series C stage. Most of the 2 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alex Colville?
Public channels for Alex Colville include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alex Colville last invest?
The most recent investment recorded for Alex Colville closed in Feb 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
